Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29120571 | 0.95 | CYP1A2 (0.38) | CYP1A2KMT2AMEN1NPC1CYP2B6 | |
| SCHEMBL14728652 | 0.82 | CYP1A2 (0.37) | CYP1A2KMT2A | |
| SCHEMBL23277743 | 0.81 | CYP1A2 (0.42) | CYP1A2 | |
| SCHEMBL26003606 | 0.79 | NPC1 (0.32) | NPC1CYP2B6 | |
| SCHEMBL8267554 | 0.79 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL1394430 | 0.77 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL16975487 | 0.77 | ALDH1A1 (0.41) | CYP1A2KMT2AMEN1 | |
| SCHEMBL12630575 | 0.77 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL1088433 | 0.77 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL14725163 | 0.77 | SIGMAR1 (0.41) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-113493628-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-2566864-B1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1442025-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003033476-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6265575-B1 | THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6251921-B1 | ADMINISTERING THROMBIN INHIBITING DIAMINE COMPOUND TO MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| US-5143935-A | Gastrointestinal disorders | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CYP1A2 1323/4885KMT2A 4021/4885MEN1 4058/4885 |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | MC1R, MCHR1, MCHR2 | CYP1A2 356/4885KMT2A 3945/4885MEN1 303/4885 |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CYP1A2 1422/4885KMT2A 3935/4885MEN1 4333/4885 |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | CYP1A2 1264/4885KMT2A 2278/4885MEN1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.